Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. (Nasdaq: VIR) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed information on its clinical programs, collaborations and financial position. This SEC filings page aggregates those documents and pairs them with AI-generated summaries to help readers understand the key points in each filing.
For Vir Biotechnology, important filings include Form 8-K current reports describing material events, such as the license agreement with Norgine Pharma UK Limited for commercial rights to the tobevibart and elebsiran combination in chronic hepatitis delta across Europe, Australia and New Zealand, and updates on clinical data from the SOLSTICE Phase 2 trial. Other 8-K filings reference quarterly financial results, including cash, cash equivalents and investments, research and development spending, and progress across the ECLIPSE registrational program and oncology pipeline.
Investors following Vir Biotechnology’s infectious disease and oncology strategy can use this page to locate quarterly and annual financial disclosures, business updates reported via 8-K, and other SEC documents that discuss collaborations, licensing arrangements and clinical milestones. AI-powered tools highlight key terms, summarize complex sections and make it easier to identify information related to chronic hepatitis delta development, PRO-XTEN dual-masked T-cell engagers, and the company’s use of platforms such as dAIsY and PRO-XTEN.
The page also provides access to filings that may include details on revenue categories such as collaboration, contract, grant and license revenue, as well as information about material agreements and clinical trial updates referenced in attached press releases. Real-time integration with EDGAR means new Vir Biotechnology filings appear here as they are made public, with concise AI explanations to support faster review and comparison over time.
Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini sold 7,711 shares of common stock in an open‑market transaction at a price of $9.12 per share on March 23, 2026. The filing shows he directly holds 61,902 shares after this sale. According to a footnote, the transaction was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 19, 2025, indicating it was scheduled in advance as part of a trading program.
Vir Biotechnology EVP & CFO Jason O'Byrne reported an internal restructuring of 5,000 shares of Common Stock, described as a transfer without consideration for estate planning purposes. The filing shows 2,500 shares moved from his direct holdings and 2,500 shares recorded as indirectly held.
After these transactions, O'Byrne holds 160,115 shares directly and 2,500 shares indirectly through the O'Byrne Family Trust, where he and his spouse serve as trustees. The Form 4 does not reflect any open‑market buying or selling, but rather a non-cash reallocation of ownership.
VIR filed a Rule 144 notice reporting proposed sales of Common Stock and recent dispositions by an insider. The filing lists restricted stock vesting events of 02/13/2026 (2,220 shares), 02/23/2026 (2,546 shares) and 02/24/2026 (2,945 shares).
The excerpt also shows recent sales by Brent Sabatini during the past three months, including 1,530 shares on 02/13/2026 and 1,829 shares on 02/23/2026
Vir Biotechnology, Inc. has expanded the role of its Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA, appointing her to the additional position of President effective March 4, 2026. She will now serve as CEO, principal executive officer, and President.
The company notes there are no arrangements or understandings with any other person related to her appointment, no family relationships with any director or executive officer, and no transactions involving her that require related-party disclosure. Biographical details are incorporated by reference from Vir’s April 17, 2025 proxy statement.
Vir Biotechnology, Inc. received an amended Schedule 13D (Amendment No. 7) from ARCH Venture-affiliated funds and related individuals updating their ownership of the company’s common stock. ARCH Venture Fund IX, L.P. and related ARCH funds together are record owners of 12,916,663 shares of common stock, representing about 8.1% of the outstanding class.
Including personal and shared holdings, Robert Nelsen reports beneficial ownership of 13,534,704 shares (8.5%), Keith Crandell 13,189,627 shares (8.3%), and Clinton Bybee 13,008,393 shares (8.1%). The percentages are based on 159,811,395 Vir Biotechnology shares outstanding, combining 139,517,278 shares outstanding as of February 17, 2026 and 20,294,117 shares issued on February 27, 2026. The filing notes shared voting and dispositive power among affiliated ARCH entities and that no reporting person has effected transactions in the stock during the last 60 days.
Vir Biotechnology director Vicki L. Sato reported selling 22,000 shares of common stock in open-market transactions. The sales occurred on March 2, 2026 at weighted average prices of $9.5039 and $9.98 per share under a pre-arranged Rule 10b5-1 trading plan. After these sales, she directly owned 1,122,391 shares.
VIR filed a Form 144 notice to sell 88,000 pre-IPO common shares. The filing lists the securities to be sold as 88,000 Pre-IPO Shares with an original date of 01/17/2017. The excerpt also shows prior 10b5-1 sales by Vicki Lee Sato: 22,000 shares on 01/02/2026, 22,000 shares on 02/02/2026, and 42,377 shares on 02/24/2026.
Vir Biotechnology, Inc. completed a public offering of common stock to raise new capital. The company sold 17,647,059 shares at $8.50 per share under an underwriting agreement with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C., and Barclays Capital Inc.
The underwriters fully exercised a 30-day option to buy an additional 2,647,058 shares. As a result, Vir Biotechnology issued a total of 20,294,117 shares of common stock, generating aggregate gross proceeds of approximately $172.5 million before underwriting discounts, commissions, and offering expenses.
Vir Biotechnology, Inc. is offering 17,647,059 shares of common stock at $8.50 per share under an underwriting agreement with Goldman Sachs, Leerink Partners, Evercore and Barclays. The offering is expected to close on February 27, 2026, subject to customary conditions.
The underwriters have a 30-day option to buy up to an additional 2,647,058 shares at the public offering price. Vir Biotechnology expects net proceeds of approximately $141.1 million, or about $162.3 million if the option is fully exercised, after underwriting discounts, commissions and estimated expenses.
Vir Biotechnology, Inc. is offering 17,647,059 shares of common stock at a public offering price of $8.50 per share, with an underwriter option to purchase up to 2,647,058 additional shares for 30 days.
The offering is expected to provide net proceeds of approximately $141.1 million (or $162.3 million if the underwriters exercise their option in full), which Vir says it will use to fund its share of global clinical development and potential commercial launch costs for VIR-5500, other TCE programs using the PRO-XTEN® platform, and for working capital and general corporate purposes.